Contact us
Let us know about your remote blood biomarker monitoring needs.
50 Milk Street
16th floor
Boston, MA 02109
contact@generalprognostics.com
A bloodless future for healthcare?
Blood tests are the gold standard for predicting disease progression. Unfortunately, blood tests may also be time consuming, expensive, and painful. What if your smartwatch could tell you when vital blood biomarkers change?
Our Purpose
GPx is enhancing remote patient management by building a new class of biomarkers called Bloodless Blood Tests. Through our AI-powered Canary Prediction Engine, digital biomarkers collected from patient wearables and peripherals transform into an unparalleled window into patient blood biomarker status. With this data, physicians benefit from presymptomatic detection of critical patient condition changes, enabling timely treatment that avoids hospital readmissions.
Our News
Find out the latest on GPx
Congratulations to all of the startups that pitched at the #HLTH2022 Startup Pitch Competition and to @OpticSurg and General Prognostics (GPX) for their well earned honors. https://twitter.com/JNJInnovation/status/1592587010065178625
Congratulations to Dr. Tran Tu Huynh, Founder & CEO, @OpticSurg, this year’s #HLTH2022 Startup Pitch Competition winner, along with all finalists! Thank you for showcasing your innovative ideas that demonstrate the potential to shape the future of #healthcare.
We're very lucky to have had @radcliffeCARDIO meet with us to discuss the potential of #bloodlessbloodtests and #CardioID.
Thank you for the opportunity!
https://www.youtube.com/watch?v=mVaTG8PjzcI
Today begins Global #HealthEquity Week (October 24-28 - http://www.himss.org/ghew) and I thought to share this quote from our very own Javier Echenique in an interview by @radcliffeCARDIO.
https://www.radcliffecardiology.com/video-index/hrx-2022-gpx-inc-novel-ai-algorithmic-remote-blood-biomarker-monitoring-patients-hf